Capital Roundtable

Marquee Sponsor

Association Partners


Data Partners


Partial List of
Past Attendees 


Atalaya Capital Mgmt.

Avalon Net Worth

B. C. Ziegler

Bass Berry & Sims

BC Partners


Blue Wolf Capital

BlueMountain Capital

Brentwood Capital


Brown Gibbons Lang

Cain Brothers

Caisse de Depot et Placement du Quebec

Capricorn Healthcare

Cascade Partners

CIT Group Inc.

Clearview Capital

Consonance Capital

Dental Care Alliance

DermCare Mgmt.

Dorilton Capital

Excellere Partners

Firmament Group

Halyard Capital Mgmt.

Harbour Point Capital

Holland & Knight

Houlihan Lokey

HT Developers

Jordan Co.

Lorient Capital

McKesson Corp.

McKinsey & Company

Michael Kelly

MidOcean Partners

NorthStar Anesthesia

OMERS Private Equity

Parkstone Growth

Plante Moran

Post Capital Partners

Pouschine Cook

Proskauer Rose

Provident Healthcare Partners

Revelstoke Capital

River Cities Capital

Riverside Company

Rivkin Radler

Sun Capital Partners

TerraNova Capital

Thompson Street

Thurston Group

Unified Physician Mgmt.

Varsity Healthcare

West Monroe

William Blair


How Orphan Drugs

And Personalized Medicines

Are Drawing Investors

To Specialty Pharmacies


 Private Equity Investing

In Specialty Pharmacy Companies




Thursday, May 30, 2019

8:00 am – 5:00 pm

New York City





Bass Berry & Sims PLC




Faculty | Schedule | Registration | Location | Sponsorship | Audio Package |

Until recently, consolidation has been the main driver of private equity activity in the specialty pharmacy industry.  But that’s changing as more and more PE firms have gotten interested.


Here are three key characteristics of specialty pharmacies that investors are finding

attractive --

  • Often their products are “orphan drugs” which treat serious “orphan diseases” that are so rare that they couldn’t be profitable without government assistance.

  • These drugs are complicated and costly to make, so they carry very high margins and price points.

  • They require special care to dispense safely.

Look at PANTHERx Specialty Pharmacy, which operates as an exclusive (or highly limited) marketing partner for a small number of specialty drug makers. Its unique treatments have made PANTHERx one of Inc. Magazine’s fastest growing companies for the third straight year, consistently ranking among the top 50 companies.


The firm works with prominent biotechnology partners such as Alexion, Neurocrine, Ultragenyx, Otsuka, and Insmed. 


Orphan drugs have been approved at a fast clip over the last couple of years. The potential of orphan drugs is just one of several developments that are drawing PE investors to specialty pharmacies. Other developments include new gene therapies soon to be coming to market, as well as precision medicine therapies, which can have price points even greater than $1m.


Click here to receive our best rate -- a savings of $300 on our regular conference rates!


Other trends include --

  • Fast growth of the specialty drug industry overall, driven by an aging population, and increased numbers of diagnoses of chronic conditions. Such drugs are projected to account for nearly 40% of total drug spend by 2020, up from 28% in 2016.

  • Easing of reimbursement pressures and increased margins as regulators address billing practices such as reconciliation between a drug’s retail cost and its manufacturers’ rebates that were hurting some pharmacies.

  • Market shift toward de-consolidation. Only four very large corporate players control 80% of the specialty pharmacy market, so drugmakers and consumers are scouting for new channels that can offer specialized services.

You’ll gain valuable insights when you register to hear our 20+ panelists assess the outlook for investing in specialty pharmacy companies at The Capital Roundtable’s all-day conference on Thursday, May 30, 2019, in midtown New York City.



Here Are Three Key Reasons Why You Should Join Us


  1. Understand what kinds of specialty pharmacies investors should avoid.

  2. Get an update on the regulatory big picture, including changes to the 340B act and the rebate safe harbor.

  3. Learn about existing and potential avenues for exits in this very consolidated industry.


Of course, all subsectors aren’t equal. Some, like hospital pharmacies, are hot, while others remain out of favor. And understanding regulatory trends and drug makers’ needs is critical to determining which kinds of companies are likely to prosper.



Click Here to Register to Hear Our 20+ Speakers Address Key Points Such As --


  • The impact of expensive new drugs coming to market

  • How pharmacy reimbursement is being tied to patient outcomes

  • The risk of negative publicity due to high prices of new orphan drugs

  • Tips for helping portfolio companies navigate the reimbursement maze

  • The new roles specialty pharmacies are taking on as drug delivery gets more complicated

  • The wide range of multiples in specialty pharmacy M&A deals

  • Whether and when direct-to-consumer trends may come to specialty pharmacies

  • How best to compete with specialty pharmacies owned by payers and by pharmacy benefit managers

  • Different business models for health system specialty pharmacies
  • When to buy and when to build in this industry

  • What to consider as your portfolio companies expand across state borders

  • How portfolio companies are refining data collection and analytics to improve bottom lines

  • Best tactics for building a professional sales force

  • Accreditation issues


Register Now to Enhance Your Awareness of Opportunities in This

Fast-Growing Market




 Recent Middle-Market Specialty Pharmacy Deals


  • Waud Capital Partners formed a platform company, Pharmacy Partners Holdings LLC, to execute a growth strategy in the specialty pharmacy market.

  • Frazier Healthcare Partners purchased a majority stake in Houston-based Southside Pharmacy, now known as AppianRx.

  • Consonance Capital Partners recapitalized Orsini Pharmaceutical Services, a “high-touch” rare disease specialty pharmacy.

  • Biomatrix Specialty Pharmacy LLC, backed by Acon Investments and Triton Pacific Capital Partners, bought Cardinal Health’s specialty division.

  • BelHealth Investment Partners sold Apothecary by Design to CVS Health.

  • Galen Partners recapitalized Miami-based SMP Pharmacy Solutions, a high-touch, service-oriented specialty pharmacy that focuses on niche and complex therapeutic areas such as fertility.

  • NewSpring, Gemini Investors, and Celerity Partners invested in Flushing, N.Y.-based Total Care Rx Inc, a specialty pharmacy focused primarily on medication for organ transplant recipients and residents in long-term care facilities.



This Capital Roundtable conference is the ideal place to expand your network and open up pathways to future deals. The day’s agenda includes ample time to let you --

  • Meet fellow attendees and featured speakers
  • Enhance your personal database with valuable new connections
  • Share both ideas and business cards
  • Meet potential investment partners and clients

Keep in mind this conference is certain to fill up quickly, so you’ll want to register as soon as possible to assure yourself a seat. To avoid disappointment, please contact Chris Agar today to confirm your attendance at 212-832-7300 ext. 0 or


 Who Should Attend


Designed to Meet the Needs of GPs, LPs, & Managers of Buyout, Growth Equity, Mezzanine, BDC, and Lending Funds, as Well as Independent Sponsors, Operating Partners, Portfolio Company Managers, and the Bankers, Lawyers, Accountants, & Other Advisors Who Support Them.




We look forward to having you join us on Thursday, May 30, 2019.


Conference Organizers


This conference is being produced by The Capital Roundtable, America’s leading conference organization focusing on “need-to-know” information for professionals in the middle-market private equity community.  For more information about The Capital Roundtable’s 30 annual conferences and other events and programs, please visit




 Speaking & Business Development Opportunities


We offer excellent speaking, marketing, and business development opportunities to reach the middle‑market private equity community. For more details, please contact Kellie Green or Claire Notton at 212-832-7300 or by email at or




Have a Question?


Please contact Melissa Layne at or 212-832-7300 ext. 0.




Who We Are


This Capital Roundtable conference in midtown, New York City, is all-business, all-targeted, all-designed to be a completely focused day of practical information and revealing insights. You’ll gain valuable insights from --

  • Three informative panel discussions
  • Two revealing keynote presentations
  • Real-world perspectives from PE investors
  • Industry outlooks from noted sector experts
  • War stories and lessons learned from experienced hands

^ Back to Top ^


Chaired By

  • TBA



Hosted By

  • Burt Alimansky, Chairman & CEO, The Capital Roundtable


  • TBA

^ Back to Top ^



  • TBA



^ Back to Top ^


Space at this conference is limited, so register as soon as possible to assure yourself a seat. To avoid disappointment, please contact Chris Agar today to confirm your attendance at 212-832-7300 ext. 0 or


Please note that The Capital Roundtable limits the number of registrants from a single firm to three.


  • Best Rate -- Early Registration -- Save $300 off the standard fee of $1495 when you register by Friday, April 12. Just $1195.


  • Incentive Registration -- save $200 off the standard fee!
    Register by Friday, May 3, and the fee for the conference is $1295.


  • Conference Rate -- $1,495 increasing to $1,595 day of conference, space permitting.


  • Group Rate -- $1095 each until Friday, May 3, when you register two or more people to attend from the same company . This rate increases to $1295 each after Friday, May 3.


Register Now


You can pay by credit card (using the links above) or by check. Mail your check and business card to: New York Business Roundtable Inc., 747 Third Avenue, Suite 200, New York, NY 10017.

Have a special question? Please contact Chris Agar at or 212-832-7300 ext. 0.


From time to time, for reasons beyond Capital Roundtable's control, program schedules and speakers become subject to change.  We make every effort to announce substantive changes by email to registrants at least 48 hours in advance.

^ Back to Top ^


Midtown, NYC

^ Back to Top ^

Audio Package

Can't attend but want to hear the program? You can buy the audio package along with the handouts. Purchase the audio package online now.

^ Back to Top ^


We offer excellent marketing and business development opportunities to reach the middle‑market private equity community. For more details, please contact Claire Notton at 212-832-7300 ext.117, or by email at


^ Back to Top ^